Coherus Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CHRS and other ETFs, options, and stocks.About CHRS
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI.
CEODenny M. Lanfear
CEODenny M. Lanfear
Employees228
Employees228
HeadquartersRedwood City, California
HeadquartersRedwood City, California
Founded2010
Founded2010
Employees228
Employees228
CHRS Key Statistics
Market cap135.98M
Market cap135.98M
Price-Earnings ratio-0.71
Price-Earnings ratio-0.71
Dividend yield—
Dividend yield—
Average volume1.83M
Average volume1.83M
High today$1.24
High today$1.24
Low today$1.10
Low today$1.10
Open price$1.18
Open price$1.18
Volume1.77M
Volume1.77M
52 Week high$2.43
52 Week high$2.43
52 Week low$0.71
52 Week low$0.71
Stock Snapshot
Coherus Oncology(CHRS) stock is priced at $1.12, giving the company a market capitalization of 135.98M. It carries a P/E multiple of -0.71.
On 2025-11-17, Coherus Oncology(CHRS) stock moved within a range of $1.10 to $1.24. With shares now at $1.12, the stock is trading +1.8% above its intraday low and -9.4% below the session's peak.
Trading activity shows a volume of 1.77M, compared to an average daily volume of 1.83M.
The stock's 52-week range extends from a low of $0.71 to a high of $2.43.
The stock's 52-week range extends from a low of $0.71 to a high of $2.43.
People also own
Based on the portfolios of people who own CHRS. This list is generated using Robinhood data, and it’s not a recommendation.